Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3136-3140

  Kojima, Saori ^a   Nadai, Masayuki ^b   Kitaichi, Kiyoyuki ^c   Wang, L I ^d   Nabeshima, Toshitaka ^a   Hasegawa, Takaaki ^c  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMIPRON; CARBAPENEM; DICLOFENAC; PANIPENEM; PANIPENEM PLUS BETAMIPRON; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BILIARY EXCRETION; CANNULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EXCRETION; DRUG MECHANISM; DRUG MONITORING; ENTEROHEPATIC CIRCULATION; EPILEPSY; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031760849     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.12.3136     Document Type: Article

References (26)

1. Booth, C. L., G. M. Pollack, and K. L. R. Brouwer. 1996. Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. Hepatology 23:771-780.
2. Bruni, J., B. J. Wilder, L. J. Willmore, R. J. Perchalski, and H. J. Villarreal. 1978. Steady-state kinetics of valproic acid in epileptic patients. Clin. Pharmacol. Ther., 24:324-332.
3. Covanis, A., A. K. Gupta, and P. M. Jeavons. 1982. Valproate: monotherapy and polytherapy. Epilepsia 23:693-720.
4. Dickinson, R. G., R. C. Harland, A. M. Llias, P. M. Rodgers, S. N. Kaufman, R. K. Lynn, and N. Gerber. 1979. Disposition of valproic acid in the rat: dose-dependent metabolism, distribution, enterohepatic recirculation and choleretic effect. J. Pharmacol. Exp. Ther., 211:583-595.
5. El-Sayed, Y. M., M. E. Abdel-Haameed, M. S. Suleiman, and N. M. Najib. 1988. A rapid and sensitive high-performance liquid chromatographic method for the determination of diclofenac sodium in serum and its use in pharmacokinetic studies. J. Pharm. Pharmacol. 40:727-729.
6. Evans, A. M., Z. Hussein, and M. Rowland. 1993. Influence of albumin on the distribution and elimination kinetics of diclofenac in the isolated perfused rat liver: analysis by the impulse-response technique and the dispersion model. J. Pharm. Sci., 82:421-428.
7. Fukuoka, Y., Y. Ikeda, Y. Yamashiro, M. Takahata, Y. Todo, and H. Narita. 1993. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob. Agents Chemother. 37:384-392.
8. Fukuyama, T., K. Yamaoka, Y. Ohata, and T. Nakagawa. 1994. A new analysis method for disposition kinetics of enterohepatic circulation of diclofenac in rats. Drug Metab. Dispos. 22:479-485.
9. Gugler, R., and G. E. von Unruh. 1980. Clinical pharmacokinetics of valproic acid. Clin. Pharmacokinet. 5:67-83.
10. Hussein, Z., A. M. Evans, and M. Rowland. 1993. Physiologic models of hepatic drug clearance: influence of altered protein binding on the elimination of diclofenac in the isolated perfused rat liver. J. Pharm. Sci. 82:880-885.
11. Insel, P. A. 1990. Analgesic-antipyretics and antiinflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout, p. 638-681. In A. G. Gilman, T. W. Rall, A. S. Nies, and P. Taylor (ed.), The pharmacological basis of therapeutics, 8th ed. McGraw-Hill, Inc., New York, N.Y.
12. Liu, M. J., and G. M. Pollack. 1993. Pharmacokinetics and pnarmacodynamics of valproate analogs in rats. II. Pharmacokinetics of octanoic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexane carboxylic acid. Biopharm. Drug Dispos. 14:325-339.
13. Naganuma, H., Y. Hirouchi, Y. Kawahara, K. Inui, Y. Tanigawara, R. Hori, and S. Kuwahara. 1991. Nephroprotective effect and its mechanism of betamipron (2) - relationships of renal excretion. Chemotherapy (Tokyo) 39: 178-189.
14. Ogiso, T., Y. Ito, M. Iwaki, and T. Yamahata. 1986. Disposition and pharmacokinetics of valproic acid in rats. Chcm. Pharm. Bull. 34:2950-2956.
15. Pollack, G. M., and K. L. Brouwer. 1991. Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat. J. Pharmacokinet. Biopharm. 19:189-225.
16. Rall, T. W., and L. S. Schleifer. 1990. Drugs effective in the therapy of the epilepsies, p. 450-453. In A. G. Gilman, T. W. Rall, A. S. Nies, and P. Taylor (ed.), The pharmacological basis of therapeutics, 8th ed. McGraw-Hill, Inc., New York, N.Y.
17. Reuter, B. K., N. M. Davies, and J. L. Wallace. 1997. Nonsteroidal antiinflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112:109-117.
18. Stierlin, H., J. W. Faigle, A. Sallmann, W. King, W. J. Richter, H. P. Kriemier, K. O. Alt, and T. Winkler. 1983. Biotransformation of diclofenac sodium (Voltaren R) in animals and in man. 1. Isolation and identification of principal metabolites. Xenobiotica 9:601-610.
19. Tabata, K., K. Yamaoka, T. Fukuyama, and T. Nakagawa. 1995. Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac. Pharm. Res. 12:880-883.
20. Tanimura, H., M. Ochiai, Y. Sugimoto, Y. Aoki, M. Nakamura, H. Nakatsuka, G. Ichimiya, Y. Kobayashi, et al. 1991. Tissue concentrations and clinical efficacy of panipenem/betamipron in surgical infections. Chemotherapy (Tokyo) 39:585-595.
21. Vajda, F. J. E., Drummer, P. M. Morris, J. J. McNeil, and P. F. Blandin. 1978. GAS chromatographic measurement of plasma levels of sodium valproate: tentative therapeutic range of a new anticonvulsant in the treatment of refractory epileptics. Clin. Exp. Pharmacol. Physiol. 5:67-73.
22. Vree, T. B., and E. van der Klejin. 1977. Pharmacokinetics and renal excretion of 2-n-propyl pentanoate in man, dog and rhesus monkey. Pharm. Weekbl. 112:290-292.
23. Wang, L., T. Hasegawa, M. Nadali, and Nabeshima. 1993. The effects of N-benzoyl-β-alanine, a new nephroprotective drug on the distribution and renal excretion of enprofylline in rats. J. Pharm. Pharmacol. 45:622-626.
24. 23a. Welfare Ministry of Japan. 1996. Adverse reaction publication 137. Welfare Ministry of Japan, Tokyo.
25. Yamaoka, K., Y. Tanigawara, T. Nakagawa, and T. Uno. 1981. A pharmacokinetic analysis program (MULTI) for microcomputer. J. PharmacobioDyn. 4:879-885.
26. Yu, H. Y. 1985. Clinical implication of serum protein binding in epileptic children during sodium valproate maintenance therapy. Ther. Drug Monit. 23:243-251.